Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Goldman Sachs Raises MRK Price Target to $160 Amid Healthcare Optimism

Guavy AI Editorial Team
Instruments
MRK
Share

Goldman Sachs has maintained its 'Buy' rating on Merck & Co (MRK), increasing the price target from $140 to $160, representing a 14.29% rise.

The analyst's updated forecast suggests confidence in MRK's future performance, driven by the company's robust pipeline of pharmaceutical products, particularly in oncology and vaccines.

This aligns with the broader market sentiment towards healthcare stocks, which have been gaining traction amid increasing demand for innovative treatments.

According to GuruFocus' GF Value, MRK is currently 27.0% overvalued at its current price of $152.19, indicating that investors may be paying a premium for the stock relative to its intrinsic value.

More on Stocks

Stocks just now

JPMorgan Chase Preps for Smooth Transition Amid Dimon's Expected Retirement

Stocks just now

JPMorgan Bolsters Tech M&A Team with Bank of America Vet David Fishman

Stocks 1m ago

Sebi Cracks Down on JPMorgan Unit, Local Brokerage Firm for CAS Manipulation

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy